Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression (Q40310448)

19 September 2017

Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression (English)

1 reference

ORCID Public Data File 2021

19 September 2017

1 reference

author name string

C M L Chan

1

1 reference

19 September 2017

B B Y Ma

2

1 reference

19 September 2017

S C Wong

3

1 reference

19 September 2017

A T C Chan

4

1 reference

19 September 2017

1 October 2005

1 reference

Biomedicine and Pharmacotherapy

19 September 2017

1 reference

19 September 2017

59 Suppl 2

1 reference

19 September 2017

S268-71

1 reference

COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib

19 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2805%2980043-5

7 January 2021

3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2805%2980043-5

7 January 2021

Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2805%2980043-5

7 January 2021

Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2805%2980043-5

7 January 2021

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2805%2980043-5

7 January 2021

Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2805%2980043-5

7 January 2021

Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2805%2980043-5

7 January 2021

Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2805%2980043-5

7 January 2021

Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2805%2980043-5

7 January 2021

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2805%2980043-5

7 January 2021

Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1,

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2805%2980043-5

7 January 2021

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2805%2980043-5

7 January 2021

10.1016/S0753-3322(05)80043-5

Identifiers

DOI

1 reference

19 September 2017

1 reference